TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7308277
Drug: Metoprolol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 300 mg once/day
Study: 31999296
Drug: High-Dose Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Chemotherapy (HDCT)
Study: 31999296
Drug: Conventional-Dose Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-Dose Chemotherapy (CDCT)
Study: 26777124
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy (AF) - 1.1+2.0 Gy/day, 5 days/week in 35 days, total dose 68 Gy
Study: 26777124
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (CF) - 2 Gy/day, 5 days/week in 49 days, total dose 68 Gy
Study: 20518928
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group I: 2 mL of distilled water
Study: 9162604
Drug: Lipid-lowering drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drugs in patients with CHD and serum cholesterol >5.5 mmol I(‐1)
Study: 9162604
Drug: Consider lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consider lipid-lowering drugs in patients without CHD when serum cholesterol exceeds 6.5 mmol I(‐1) and CHD risk >20% over the next 10 years
Study: 9162604
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy aimed at decreasing fat intake, particularly saturated fat, and weight reduction in the obese
Study: 29708630
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% cream
Study: 29708630
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of diprospan combined with topical timolol 0.5% cream
Study: 26079636
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS combined with occupational therapy
Study: 26079636
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS combined with occupational therapy
Study: 24763401
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment response assessed by leukemic blast counts in bone marrow on day 28 after first reinduction.
Study: 24763401
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment response assessed by leukemic blast counts in bone marrow on day 15 after first reinduction.
Study: 17109859
Drug: Outpatient Thermachoice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient Thermachoice III with ibuprofen 800 mg pre-treatment and nitrous oxide rescue analgesia
Study: 16331821
Drug: TCI remifentanil‐propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI remifentanil‐propofol (remifentanil at 6 microg/L and propofol at 3 mg/L)
Study: 16331821
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (fentanyl 2.5 microg/kg and propofol 1‐2 mg/kg, maintained with fentanyl 0.03 microg.kg(‐1).min(‐1) and 1% isoflurane)
Study: 9862539
Drug: Percutaneous intramuscular
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous intramuscular stimulation
Study: 30973188
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg
Study: 23082002
Drug: Vismodegib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (150 mg/day orally) with FOLFOX or FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Study: 23082002
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with FOLFOX or FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Study: 8201151
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin therapy
Study: 8772731
Drug: Intensified Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified Conventional Insulin Treatment (ICT)
Study: 8772731
Drug: Standard Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Insulin Treatment (ST)
Study: 1595825
Drug: Adaptive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive group (n = 23) received individual training in food preparation activities
Study: 6529680
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg X kg‐1
Study: 6529680
Drug: Midazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4 mg X kg‐1
Study: 28194841
Drug: Sildenafil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil treatment in HFpEF patients
Study: 26464415
Drug: EA+LA (Electroacupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA+LA (Electroacupuncture after injection of local anaesthetics)
Study: 24263121
Drug: Atropine (0.2-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.2-1 mg) during DSE
Study: 21864414
Drug: Psycho-social intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psycho-social intervention consisting of 12 sessions of structured social support, problem solving techniques, group discussions, and trainer-supervised relaxation exercises (twice per week over six weeks)
Study: 19212235
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded dental implants
Study: 19212235
Drug: Conventionally loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally loaded dental implants
Study: 11555565
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aerosolized tobramycin solution for inhalation (TSI) administered twice daily for 4 weeks
Study: 11555565
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aerosolized tobramycin solution for inhalation (TSI)
Study: 23923408
Drug: Methotrexate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (10 mg) single morning dose
Study: 23923408
Drug: Mini pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini pulse betamethasone (5 mg) single morning dose on 2 consecutive days
Study: 16515981
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA less than 1 ng/ml
Study: 16515981
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 1.0 to 1.99 ng/ml
Study: 16515981
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 2.0 to 2.99 ng/ml
Study: 16515981
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 3.0 to 4.0 ng/ml
Study: 16515981
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with baseline PSA less than 1 ng/ml converting to PSA more than 4 ng/ml
Study: 16515981
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with baseline PSA less than 1 ng/ml and negative baseline DRE
Study: 10691220
Drug: M‐6‐G 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐6‐G 0.1 mg/kg
Study: 1972381
Drug: Morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.15 mg/kg
Study: 9488217
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) at doses of 0.3, 1.0, and 3.0 microg/kg per min
Study: 9488217
Drug: Atropine at
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine at doses of 100 and 300 ng/kg per min
Study: 8442923
Drug: Chemotherapy (tinidazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (tinidazole, thiabendazole, and cotrimoxazole)
Study: 2908258
Drug: Chloroquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (300 mg per week)
Study: 29914406
Drug: Management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies by general practitioners (GPs) during MUS consultations, including history-taking, physical examination (24.5%), additional investigations by the GP (11.1%), prescribing medication (24.6%), and providing explanations (11.2%).
Study: 24919867
Drug: Data from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data from the Clinical Antipsychotic Trial of Intervention and Effectiveness
Study: 20651386
Drug: Prospective follow‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective follow‐up without treatment
Study: 18614918
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) adherence measured through pill usage and questionnaire.
Study: 18614918
Drug: Complete adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete adherence (100% drug possession ratio).
Study: 12626218
Drug: 5-cm² Estradot
Normalized name: estradiol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-cm² Estradot patch (50 micro g/day)
Study: 12626218
Drug: 12.5-cm² Climara
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5-cm² Climara patch
Study: 12626218
Drug: 5-cm² Estradot
Normalized name: estradiol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-cm² Estradot patch
Study: 12626218
Drug: Both patches
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both patches
Study: 10652894
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg) tablets administered twice daily
Study: 10652894
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg) tablets administered thrice daily
Study: 6149772
Drug: Dextroamphetamine 30
Normalized name: dextroamphetamine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 30 mg
Study: 31695864
Drug: MART (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: MART (maintenance and reliever therapy)
Study: 29193710
Drug: Scopolamine ointment
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine ointment
Study: 25172200
Drug: Collagen sponge
Normalized name: Absorbable collagen sponge bone graft product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen sponge without antibiotics
Study: 11907654
Drug: Rapid fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid fat infusion over 6 h (rFI)
Study: 11907654
Drug: Slow fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow fat infusion over 24 h (sFI)
Study: 10208786
Drug: No intra-aortic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intra-aortic balloon pump therapy
Study: 2365119
Drug: Piperacillin or
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin or Mezlocillin (single-dose prophylaxis)
Study: 330077
Drug: timolol (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: timolol (20, 40, and 60 mg daily)
Study: 330077
Drug: propranolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (0.2 mg/kg intravenously)
Study: 7245774
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg slow-release allopurinol
Study: 29474280
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of oral phenazopyridine
Study: 22412865
Drug: Late exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late exposure group (LEG) - Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months
Study: 20631460
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 1% gel (DSG) applied 4 g, 4 times daily
Study: 20631460
Drug: Vehicle (control)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control) applied 4 g, 4 times daily
Study: 21174485
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 1% gel (DSG)
Study: 17397001
Drug: peginterferon-alpha 2a/ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon-alpha 2a/ribavirin therapy
Study: 15719490
Drug: Raltitrexed at
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed at a dose of 2.5 mg/m(2) intravenously (i.v), once every 3 weeks, for two doses, combined with standard radiotherapy of 70 Gy over 7 weeks.
Study: 15719490
Drug: Raltitrexed at
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed at a dose of 2.5 mg/m(2) given twice 3 weeks apart, combined with 70 Gy of radiotherapy.
Study: 12112183
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 2 x 240 mg
Study: 7749498
Drug: Standard intensive
Normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensive treatment and patient education with the distress reduction program
Study: 7749498
Drug: Standard intensive
Normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensive treatment and patient education without the distress reduction program
Study: 373084
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 600 mg daily
Study: 1096276
Drug: Phenylbutazone 300
Normalized name: phenylbutazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 300 mg daily
Study: 373084
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 1,500 mg daily
Study: 28009472
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg for 1 month (TP1)
Study: 28009472
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg (TP2)
Study: 28009472
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg (TP1)
Study: 19753648
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg/day for 5-7 days)
Study: 19753648
Drug: Triple group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple group (GM-CSF 10 microg/kg/day on 1st and 2nd day, G-CSF 5 microg/kg/day for 5-7 days, and darbepoetin-alpha 40 mg on 1st day)
Study: 17499604
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice daily) + Esomeprazole (20 mg twice daily)
Study: 17499604
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice daily) + Placebo
Study: 12468168
Drug: Lidocaine ointment
Normalized name: Lidocaine Ointment
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine ointment
Study: 9655734
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplementation (75 mg vitamin E, 650 mg vitamin C, 15 mg beta carotene)
Study: 7649323
Drug: Adjuvant alpha‐interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant alpha‐interferon treatment (once a week for 8 weeks)
Study: 7649323
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant interferon treatment (control group)
Study: 2501765
Drug: Insulin bolus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin bolus (n = 24)
Study: 2501765
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin bolus (n = 32)
Study: 588388
Drug: Pentolinium tartrate
Normalized name: pentolinium tartrate
DrugBank: Pentolinium (DB01090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentolinium tartrate (Ansolysen) in doses of 10-15 mg
Study: 29688121
Drug: RV3-BB vaccine
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB vaccine (three doses, first dose at 0-5 days after birth)
Study: 29688121
Drug: RV3-BB vaccine
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB vaccine (three doses, first dose at about 8 weeks after birth)
Study: 28729014
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium fluorescein
Study: 21428727
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 or 50 mg, depending on renal function)
Study: 26041585
Drug: Glimepiride (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (titrated doses)
Study: 18328440
Drug: Commercial MCT‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial MCT‐enriched dietary supplements
Study: 15902724
Drug: Fuzhenghuayu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzhenghuayu capsule
Study: 15902724
Drug: Heluoshugan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heluoshugan capsule
Study: 14630567
Drug: CDP860 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP860 (25 mg/kg)
Study: 11550107
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (n = 2882)
Study: 1511192
Drug: Dry group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry group (fluid administration: 50, 60, 70, 80, 90, 100 and 120 ml/kg/day during the first week and 150 ml/kg/day until aged four weeks)
Study: 1511192
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (fluid administration: 80, 100, 120 and 150 ml/kg/day during the first week and 200 ml/kg afterwards)
Study: 30160627
Drug: LOW (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW (9 weekly sets, 1 session per week)
Study: 30160627
Drug: MOD (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD (18 weekly sets, 2 sessions per week)
Study: 30160627
Drug: HIGH (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH (27 weekly sets, 2 sessions per week)
Study: 23547239
Drug: Biomarker combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker combinations centered on insulin‐like growth factor acid labile subunit
Study: 20970976
Drug: MK-0633 100
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0633 100 mg
Study: 18713501
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) for 6 months, offered to 568 subjects, with 565 accepting.
Study: 18713501
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) with counseling and monthly follow-up.
Study: 16540519
Drug: 3.5 ml
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 ml of alcohol gel
Study: 16540519
Drug: 1.75 ml
Normalized name: ALCOHOL 1.75 mL TOPICAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75 ml of alcohol gel
Study: 14571789
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon alfa-2a (4.5 MU thrice weekly) and amantadine (200 mg daily)
Study: 14571789
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy alone (4.5 MU thrice weekly)
Study: 14571789
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon alfa-2a and amantadine
Study: 14571789
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy alone
Study: 10736080
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (M)
Study: 10736080
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine with butorphanol (M+B)
Study: 8726243
Drug: Pravastatin 5
Normalized name: pravastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 5 mg/d
Study: 3034623
Drug: Calcium entry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium entry blockers PY 108‐068 (PY)
Study: 3034623
Drug: Calcium entry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium entry blockers PN 200‐110 (PN)
Study: 25794636
Drug: Clinical Case
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Case Management with Problem-Solving Therapy (CM-PST)
Study: 26576808
Drug: Meridian balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meridian balanced method electroacupuncture (BMEA) + Traditional Chinese Medicine Health Consultation (TCM HC)
Study: 26576808
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine Health Consultation (TCM HC)
Study: 12685514
Drug: Trandolapril (Tra)
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril (Tra) 2 mg
Study: 12685514
Drug: Quinapril (Qui)
DrugBank: Quinapril (DB00881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinapril (Qui) 20 mg
Study: 10073329
Drug: OROS oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS oxybutynin chloride 5 mg once daily for 4 days